CORT Latest Headlines

Corcept Therapeutics Hit By Shareholder Investigation As FDA Rejection Erases $3.6 Billion in Value

Market Chameleon (Thu, 22-Jan 11:19 AM)

Corcept’s Phase 3 ROSELLA Trial Shows Significant Survival Benefit for Relacorilant in Platinum-Resistant Ovarian Cancer

Market Chameleon (Thu, 22-Jan 8:45 AM)

FDA Requests More Data for Corcept’s Relacorilant, Prompting Rethink of Approval Path

Market Chameleon (Fri, 2-Jan 10:30 AM)

FDA Requests More Data on Corcept’s Relacorilant for Hypercortisolism—What’s Next for This Promising Cortisol Modulator?

Market Chameleon (Wed, 31-Dec 8:19 AM)